Clinical Trial Update: Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating oral ruxolitinib (INCB018424) in patients with androgen independent metastatic prostate cancer was terminated; results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2012-01-20